logo
Fancy a ferry from Scotland to France? ‘Project Brave' wants to take you there in 2025

Fancy a ferry from Scotland to France? ‘Project Brave' wants to take you there in 2025

Euronews27-02-2025
Hopes for a new direct ferry service between Scotland and France have resurfaced, but without any concrete moves towards launch.
The planned service will provide three weekly sailings from the port of Rosyth near Edinburgh to Dunkirk in France. Proposals for the so-called 'Project Brave' ferry service were first floated in 2022, but stalled due to lack of funding.
Now, talks of funding the initiative have restarted, as supporters argue that the link would have massive economic benefits, both from transportation of passengers and the movement of freight.
For tourists, it would provide a convenient travel option, with the possibility of taking a vehicle on the crossing, giving more flexibility at the other end. Given that it would be an alternative to road and air transport, it would also align with goals to reduce carbon emissions.
'Industry agrees and ferry operators stand ready to deliver a route, but the Scottish government lacks the courage to support Project Brave,' claims Neale Hanvey, former leader of the Alba party.
'What can be done to encourage the Scottish government to invest a modest amount of pump-prime funding to realise the economic and environmental benefits that would be felt by all across the UK?'
If the service were to launch, it would be a crossing of around 20 hours, making it one of the longest sea journeys in Europe. The current longest crossing is from Portsmouth, UK, to Bilbao, Spain, which takes between 27 and 30 hours.
When did Scotland last have a direct ferry to Europe?
From 2002, Scotland had a direct ferry connection to Zeebrugge in Belgium from its port in Rosyth. Operated by Superfast Ferries, the service was an overnight crossing of around 17 hours, departing around four times per week.
Although the summer months saw good demand for the service from passengers, concerns mounted over the lack of freight on the crossing. In 2005, the crossing frequency was reduced to just three times per week.
The following year, Superfast Ferries adjusted its vessel from the Superfast X to the smaller Blue Star I, operated by its sister company Blue Star Ferries. Then, in 2008, the service was discontinued entirely.
Unperturbed by the poor performance of the route, Norfolkline, a subsidiary of Danish company DFDS, picked up the service in 2009 with a three weekly overnight crossing. But that didn't last long either, as DFDS pulled the passenger service from the route in 2010, citing insufficient demand.
DFDS continued to run a freight-only service between Rosyth and Zeebrugge until 2018, when it closed following a fire on board its freight ship.
When will the new Scotland to France ferry launch?
Although there is some support for a direct Rosyth to Dunkirk ferry service, its launch is not without its hurdles.
According to the Dunfermline Press, the original Spring 2025 launch date has been delayed and pushed back as DFDS is seeking grants from the Scottish Government to help launch the route.
However, when DFDS previously tried to obtain funding to support the route, Transport Scotland concluded that subsidising routes in such a way could be deemed 'anti-competitive.'
At Westminster in November, Graeme Downie MP said £3 million (€3.6 million) in funding was needed, adding that "It is estimated the direct ferry link would initially carry 51,000 passengers a year, rising to 79,000, bringing an additional £11.5 million (€14 million) of spend to the Scottish economy.'
According to a spokesperson for DFDS, it is continuing to discuss the opportunity with the Scottish government, with conversations ongoing around 'practical issues which will have to be resolved before any new ferry service can be introduced.'
'As it stands, the timeframe is currently looking like the second half of 2025,' the spokesperson concludes.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Pandora second quarter operating profit in line with forecast, keeps 2025 outlook
Pandora second quarter operating profit in line with forecast, keeps 2025 outlook

Fashion Network

time2 days ago

  • Fashion Network

Pandora second quarter operating profit in line with forecast, keeps 2025 outlook

By Reuters Danish jewellery maker Pandora posted second-quarter operating profit in line with expectations on Friday, and stuck to its full-year growth forecast. "In these turbulent times, we are satisfied with yet another quarter of high single-digit organic growth and strong profitability," CEO Alexander Lacik said in a statement. "Despite the macroeconomic challenges to top and bottom line, we are confident that we will deliver on our targets for the year driven by an exciting product pipeline, new marketing campaigns and operational agility," he said. Operating profit for the second quarter was 1.29 billion Danish crowns ($201.6 million), the same as forecast by analysts in a poll gathered by the company. Organic revenue growth stood at 8%, also in line with analyst expectations. ​ The charm bracelet maker stuck to its full-year guidance of 7-8% organic sales growth and an operating profit margin at around 24%. © Thomson Reuters 2025 All rights reserved.

Pandora second quarter operating profit in line with forecast, keeps 2025 outlook
Pandora second quarter operating profit in line with forecast, keeps 2025 outlook

Fashion Network

time2 days ago

  • Fashion Network

Pandora second quarter operating profit in line with forecast, keeps 2025 outlook

Danish jewellery maker Pandora posted second-quarter operating profit in line with expectations on Friday, and stuck to its full-year growth forecast. "In these turbulent times, we are satisfied with yet another quarter of high single-digit organic growth and strong profitability," CEO Alexander Lacik said in a statement. "Despite the macroeconomic challenges to top and bottom line, we are confident that we will deliver on our targets for the year driven by an exciting product pipeline, new marketing campaigns and operational agility," he said. Operating profit for the second quarter was 1.29 billion Danish crowns ($201.6 million), the same as forecast by analysts in a poll gathered by the company. Organic revenue growth stood at 8%, also in line with analyst expectations. ​ The charm bracelet maker stuck to its full-year guidance of 7-8% organic sales growth and an operating profit margin at around 24%.

Novo Nordisk keeps growing, fuelling hopes of a stock rebound
Novo Nordisk keeps growing, fuelling hopes of a stock rebound

Euronews

time06-08-2025

  • Euronews

Novo Nordisk keeps growing, fuelling hopes of a stock rebound

Novo Nordisk reported results for the first half of 2025 on Wednesday, days after issuing a profit warning that triggered a 23% single-day share price plunge — the steepest in its history. The results were broadly in line with expectations. In the first six months of 2025, Novo Nordisk's sales increased by 16% in Danish kroner and by 18% at constant exchange rates (CER) to DKK 154.9bn (€20.77bn). US sales climbed 16% in kroner (17% at CER), boosted by accounting changes. This included a DKK 3bn (€402 million) provision in the second quarter linked to the US' 340B drug discount scheme. International sales also rose 16% (19% at CER). Sales in Diabetes and Obesity care, meanwhile, grew 16% to DKK 145.4bn (€19.49bn), driven by a 56% surge in obesity treatments to DKK 38.8 billion (€5.2bn). GLP-1 diabetes drugs rose 8%, and rare disease sales increased 14%. Valuation slump In July 2024, Danish pharmaceutical giant Novo Nordisk briefly touched a €600bn valuation, becoming Europe's most valuable company and even surpassing its country's gross domestic product. Just over a year later, its market capitalisation has collapsed to around €180bn, as cracks begin to emerge in the blockbuster narrative surrounding its weight-loss drugs. Yet some Wall Street analysts argue the sell-off may have gone too far. At current levels, they suggest the company could be entering value territory, potentially offering a compelling buying opportunity. Forecasts for the year ahead Looking ahead, Novo Nordisk's 2025 sales are expected to grow 8–14% at CER, with operating profit up 10–16%. Currency effects are seen trimming those gains by 3 and 5 percentage points respectively. The lowered forecast reflects reduced demand for GLP-1 diabetes and weight-loss therapies due to alternative products from competitors — especially affecting Wegovy and Ozempic in the US and selected global markets. Meanwhile, leadership changes at Novo Nordisk will take effect this Thursday. After Lars Fruergaard Jørgensen was ousted in May linked to the firm's falling share price, Maziar Mike Doustdar will take over as CEO this week. Analysts eye buying opportunity after historic sell-off Goldman Sachs analyst James Quigley noted that the results were largely in line with the pre-release and exchange-rate pressures on operating profit were slightly less severe than initially feared. However, the firm flagged the discontinuation of several pipeline assets. These are individually minor, but collectively raising some concern about long-term research and development momentum. Quigley remained broadly optimistic on Novo Nordisk's long-term potential growth: "At the current level, we believe the sell-off is disconnected from the long-term opportunity in the obesity market, particularly given the significant manufacturing infrastructure and investments Novo is making or has already made.' Goldman Sachs acknowledged that uncertainties remain around the GLP-1 and obesity market, as well as Novo Nordisk's pipeline strength, particularly in light of the eventual semaglutide patent expiry. The firm said it would continue tracking key data points and developments closely. Still, Quigley added that, following the sharp share price drop, the risk-reward balance had shifted favourably. "On balance, we see more upside than downside risk and remain Buy-rated," the note read, with a DKK 400 (€53.62) target price implying about 29% upside from current levels. Market reaction Novo Nordisk shares were trading 2% lower during European morning trading on Wednesday, eyeing their seventh negative day out of the last eight. Shares are now down over 65% compared with a year ago.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store